<
>
iCAD is a global leader in advanced breast cancer detection solutions built on artificial intelligence that empower radiologists to find cancers earlier while improving reading workflow. Our Breast Health Solutions suite delivers powerful detection and workflow solutions for 2D and 3D mammography.
We applaud the FDA’s recent announcement of a national dense breast reporting standard.
Ready to standardize your read? Learn more about PowerLook® Density Assessment.
May 18, 2023
iCAD’s Breast AI Suite Wins U.S. General Services Administration’s AI Healthcare Challenge Award
May 15, 2023
iCAD Reports Financial Results for First Quarter Ended March 31, 2023
May 11, 2023
New Long-Term Real-World Research Confirms Xoft Skin eBx is as Safe and Effective as Mohs Surgery
May 1, 2023
iCAD to Report First Quarter 2023 Financial Results on May 15, 2023
Our Breast AI Suite offers a triple threat of clinically proven cancer detection, density assessment, and risk evaluation solutions, expertly designed to accelerate discovery and improve outcomes. See why leading imaging facilities worldwide trust our technologies to detect cancer and stop it in its tracks – streamlining workflow, improving accuracy, and personalizing results like never before.
iNFORMED - BlogInform, connect and engage. We invite you to engage with us to participate on the topic of cancer detection solutions, patient stories, clinical expertise.View Blog
Media SpotlightThe New Normal - The Imaging Landscape in Late-Stage Pandemic DaysView Article
Clinical FeatureImproving reading time of digital breast tomosynthesis with concurrent computer aided detection.View White Paper
© iCAD Inc. All rights reserved. iCAD, the iCAD logo, PowerLook, ProFound AI, ProFound, Xoft, the Xoft logo, Axxent, Electronic Brachytherapy System and eBx are registered trademarks of iCAD, Inc. Reproduction of any of the material contained herein in any format or media without the express written permission of iCAD, Inc. is prohibited.
<
>